 |
Health & VeritasAuthor: Yale School of Management
Howard Forman and Harlan Krumholz, two Yale physician-professors, discuss the latest news and ideas in healthcare and seek out the truth amid the noise. Produced with the Yale School of Management and the Yale School of Public Health. New episodes are available every Thursday. Language: en Genres: Business, Health & Fitness, Medicine Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
The Future of Heart Care with Aakriti Gupta
Episode 236
Thursday, 10 September, 2026
Howie and Harlan are joined by cardiologist Aakriti Gupta to discuss advances in minimally invasive heart valve treatment, her work to expand access to cardiovascular care through technology and AI, and a major clinical trial on aortic valve replacement. Howie examines claims that immigration is driving the surge in measles cases; Harlan discusses disappointing trial results for two drugs aimed at preventing cardiovascular disease. Show notes: September 11 9/11 Memorial & Museum: Marking the 25th Anniversary Measles CDC: Measles Cases and Outbreaks" "No evidence linking illegal immigration to measles outbreak, despite Byron Donalds' comment". "Kindergarten Routine Vaccination Rates Continue to Decline" "'Real-life consequences': Pennsylvania Gov. Shapiro, RFK Jr. spar over measles-associated deaths" "Two unvaccinated people die of measles in Pennsylvania" Aakriti Gupta Center for Outcomes Research & Evaluation (CORE) Structural Heart Disease Structural Heart Disease and Interventional Cardiology Heart Valve Disease Open-Heart Surgery Transcatheter aortic valve replacement (TAVR)" "Gender Bias in Choosing Cardiology, Training and Early Career Development" Rajendra Makkar Tia Health Jeff Wessler Heartbeat Health Echocardiogram iCardio.ai AllHeart BELIEVERS trial Failed Drug Trials "Novo Nordisk stops two cardiovascular studies aimed at lowering inflammation" "Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease" Lipoprotein(a) GLP-1 Agonists
